The Manufacturers Life Insurance Company Has $639,000 Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

The Manufacturers Life Insurance Company lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 140.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 40,356 shares of the company’s stock after buying an additional 23,550 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.10% of Keros Therapeutics worth $639,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. AlphaQuest LLC lifted its stake in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after buying an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Keros Therapeutics during the fourth quarter worth approximately $90,000. Exchange Traded Concepts LLC bought a new position in shares of Keros Therapeutics during the fourth quarter worth approximately $99,000. Finally, CANADA LIFE ASSURANCE Co increased its holdings in shares of Keros Therapeutics by 207.8% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock worth $116,000 after purchasing an additional 4,976 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Wall Street Analyst Weigh In

KROS has been the topic of several recent research reports. Wedbush reaffirmed a “neutral” rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Tuesday, April 1st. Oppenheimer lowered their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a report on Thursday, January 16th. Piper Sandler lowered their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. Truist Financial lowered their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Finally, HC Wainwright lowered their target price on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $14.03 on Friday. The company’s 50 day simple moving average is $12.38 and its 200 day simple moving average is $23.44. The stock has a market capitalization of $569.83 million, a price-to-earnings ratio of -2.69 and a beta of 1.32. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $211.25 million for the quarter, compared to analysts’ expectations of $84.62 million. During the same period last year, the firm posted ($1.21) earnings per share. As a group, analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business’s stock in a transaction on Wednesday, April 9th. The shares were purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. This represents a 27.01% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 22.90% of the company’s stock.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.